Clearance of Amyloid-Beta in Alzheimer’s Disease: Shifting the Action Site from Center to Periphery

Lessons from immunotherapy for Alzheimer disease

(2014) Yan-Jiang Wang   Nature Reviews Neurology

Antiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road?

(2014) Eric Karran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: Implications for amyloid-modifying therapies

(2013) Fabrizio Piazza et al.   ANNALS OF NEUROLOGY

Enhanced Proteolytic Clearance of Plasma A  by Peripherally Administered Neprilysin Does Not Result in Reduced Levels of Brain A  in Mice

(2013) J. R. Walker et al.   JOURNAL OF NEUROSCIENCE

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

(2013) Richard Dodel et al.   LANCET NEUROLOGY

Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease

(2013) Herve Rhinn et al.   NATURE

PDK1 decreases TACE-mediated α-secretase activity and promotes disease progression in prion and Alzheimer's diseases

(2013) Mathéa Pietri et al.   NATURE MEDICINE

CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology

(2013) Elizabeth M Bradshaw et al.   NATURE NEUROSCIENCE

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice

(2012) Frédérique Bard et al.   EXPERIMENTAL NEUROLOGY

Human Serum Albumin Can Regulate Amyloid-β Peptide Fiber Growth in the Brain Interstitium

(2012) Helen F. Stanyon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

(2012) Reisa Sperling et al.   LANCET NEUROLOGY

Deciphering the mechanism underlying late-onset Alzheimer disease

(2012) Dimitrije Krstic et al.   Nature Reviews Neurology

Association of Alzheimer Disease Pathology with Abnormal Lipid Metabolism: The Hisayama Study

(2012) G. T. Lesser   NEUROLOGY

Amyloid β Levels in Human Red Blood Cells

(2012) Takehiro Kiko et al.   PLoS One

Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver

(2012) N. Sehgal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer’s disease study cohorts from phase 3 trials of semagacestat and solanezumab

(2011) Christopher Carlson et al.   Alzheimers & Dementia

Autoreactive-Aβ antibodies promote APP β-secretase processing

(2011) Juan Deng et al.   JOURNAL OF NEUROCHEMISTRY

Naturally Occurring Autoantibodies against  -Amyloid: Investigating Their Role in Transgenic Animal and In Vitro Models of Alzheimer's Disease

(2011) R. Dodel et al.   JOURNAL OF NEUROSCIENCE

Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease

(2011) Adam C Naj et al.   NATURE GENETICS

Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease

(2011) J. Li et al.   NEUROLOGY

Molecular basis for amyloid-  polymorphism

(2011) J.-P. Colletier et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intramuscular delivery of a single chain antibody gene prevents brain Aβ deposition and cognitive impairment in a mouse model of Alzheimer’s disease

(2010) Yan-Jiang Wang et al.   BRAIN BEHAVIOR AND IMMUNITY

Conformations and Biological Activities of Amyloid Beta Peptide 25-35

(2010) L. Millucci et al.   CURRENT PROTEIN & PEPTIDE SCIENCE

Immunotherapy for Alzheimer’s disease

(2010) D. Morgan   JOURNAL OF INTERNAL MEDICINE

Circulating neprilysin clears brain amyloid

(2010) Yinxing Liu et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

Autoantibodies recognizing native MOG are closely associated with active demyelination but not with neuroinflammation in chronic EAE

(2010) Shin Ohtani et al.   NEUROPATHOLOGY

Amyloid-targeted therapeutics in Alzheimer's disease: Use of human albumin in plasma exchange as a novel approach for abeta mobilization

(2009) M. Boada et al.   DRUG NEWS & PERSPECTIVES

Expression of Neprilysin in Skeletal Muscle Reduces Amyloid Burden in a Transgenic Mouse Model of Alzheimer Disease

(2009) Yinxing Liu et al.   MOLECULAR THERAPY

Fatty acids, lipid metabolism and Alzheimer pathology

(2008) Carlijn R. Hooijmans et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system

(2008) Ryan N. Dilger et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Intramuscular delivery of a single chain antibody gene reduces brain Aβ burden in a mouse model of Alzheimer's disease

(2007) Yan-Jiang Wang et al.   NEUROBIOLOGY OF AGING